title: HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.
abstract: OBJECTIVE
  To compare mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART.
  
  
  METHODS
  HIV-infected adults initiating a protease inhibitor-containing treatment between 1997 and 1999 were selected in the Agence Nationale de Recherches sur le Sida et les hepatites virales (ANRS) APROCO and AQUITAINE cohorts. CD4 cell counts were estimated during follow-up using a 2-phase mixed linear model. Standardized mortality ratios (SMRs) were computed in reference to the 2002 French population rates, overall and for the time period spent with a CD4 count >or=500 cells/mm3. To identify if and when mortality rates reached values of the general population, SMRs were computed successively with truncation at each year of follow-up.
  
  
  RESULTS
  The 2,435 adults (77% men, baseline median age = 36 years, and baseline median CD4 count = 270 cells/mm3) had a median follow-up of 6.8 years. The SMR was 7.0 (95% confidence interval [CI]: 6.2 to 7.8). During the 5,402 person-years spent with a CD4 count >or=500 cells/mm3, the mortality reached the level of the general population after the sixth year after cART initiation (SMR = 0.5, 95% CI: 0.1 to 1.6).
  
  
  CONCLUSIONS
  Although overall mortality was higher in cART-treated HIV-infected adults, a subgroup with especially good prognosis can be identified, and these characteristics should be targeted for long-term treatment.
authors.affiliation: INSERM, U593, Bordeaux , France. charlotte.lewden@isped.u-bordeaux2.fr
authors.forename: Charlotte
authors.initials: C
authors.lastname: Lewden
authors.forename: Genevieve
authors.initials: G
authors.lastname: Chene
authors.forename: Philippe
authors.initials: P
authors.lastname: Morlat
authors.forename: Francois
authors.initials: F
authors.lastname: Raffi
authors.forename: Michel
authors.initials: M
authors.lastname: Dupon
authors.forename: Pierre
authors.initials: P
authors.lastname: Dellamonica
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Francois
authors.initials: F
authors.lastname: Dabis
authors.forename: Catherine
authors.initials: C
authors.lastname: Leport
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality*; D006801:Humans; D008297:Male; D013997:Time Factors
chemical_list: D044966:Anti-Retroviral Agents